[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

Results for the censored population (with 95% CI); excludes crossover patients. [12] ATAC: Arimidex, Tamozifen, Alone or in Combination; BIG: Breast International Group; DFS: Disease-free survival ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

ARIANNA 1 is a non-steroidal aromatase inhibitor, which reduces the amount ... Do not take ARIANNA 1 if you are allergic to: Anastrozole, the active ingredient of ARIANNA 1 Any of the other ...

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node ...

Arimidex (anastrozole) is a brand-name oral tablet prescribed for certain forms of breast cancer. Arimidex has interactions with some other drugs and certain supplements. Examples include ...

Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an ...

The product, T+Ai™ , is a combination of two registered agents (testosterone and anastrozole, a low dose aromatase inhibitor) that when dosed, provides three months of continuous medication ...

Arimidex has also been approved as adjuvant therapy -- drugs given after surgery or radiation-- for women with certain types of early breast cancer. Aromatase inhibitors work differently than ...